Newron Pharmaceuticals S.p.A.

NWRN

IT0004147952

Pharmaceuticals

Delayed Swiss Exchange Other stock markets 07:01:20 2024-04-25 am EDT			5-day change	1st Jan Change
6.83 ^CHF	-2.43%		+2.25%	+37.98%

Apr. 17	Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member	CI
Mar. 19	Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Newron Pharmaceuticals : launches a private placement of new shares.

September 25, 2017 at 12:05 pm EDT

Investors and Media - Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A. published this content on 25 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 September 2017 16:04:06 UTC.

Original documenthttp://www.newron.it/user/download.aspx?FILE=OBJ00772.PDF&TIPO=FLE&NOME=25Sept_Transaction_announcement_EN

Public permalinkhttp://www.publicnow.com/view/A2AA53835AD4A695B32645BE65ACBC3D5C1E0A93

Latest news about Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member	Apr. 16	CI
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Transcript : Newron Pharmaceuticals S.p.A., 2023 Earnings Call, Mar 19, 2024	Mar. 19
Newron Pharmaceuticals' FY23 Loss Narrows; Revenue Up	Mar. 19	MT
Newron Pharmaceuticals S.p.A. Announces Agreement with the European Investment Bank to Extend the Near-Term Tranche Repayment Dates of Its 2018 Financing Agreement	Mar. 15	CI
Newron Pharmaceuticals Secures Extension on Three Loan Repayments	Mar. 15	MT
Newron Pharmaceuticals Investor Subscribes for Nearly EUR6 Million Shares	Mar. 15	MT
Swiss Equities Edge Higher as Markets Continue to Weigh Rate Cut Outlook	Jan. 04	MT
Transcript : Newron Pharmaceuticals S.p.A. - Special Call	Jan. 04
Newron Reports Exceptional One-Year Results of Study 014/15 with Evenamide in Treatment-Resistant Schizophrenia	Jan. 04	CI
Newron Pharmaceuticals' Schizophrenia Drug Lowers Disease Severity in Clinical Studies	Jan. 04	MT
Swiss Equities Rally as Economic Barometer Hits Eight-month High at Year-end	Dec. 29	MT
Newron Pharmaceuticals Completes Enrolment of Schizophrenia Patients for Evenamide Clinical Study	Dec. 29	MT
Newron Pharmaceuticals S.p.A. Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A with Evenamide	Dec. 29	CI
Newron Pharmaceuticals S.P.A. Presents New Data from Study 014/015 Evaluating Its Investigational Drug Evenamide for the Management of Treatment Resistant Schizophrenia	23-10-09	CI
Newron Pharmaceuticals S.p.A. Appoints Margarita Chavez as Board Advisor	23-10-02	CI
Newron Pharmaceuticals S.p.A.(SWX:NWRN) added to S&P Global BMI Index	23-09-18	CI
Newron Pharmaceuticals Net Loss Narrows in H1; Revenue Grows	23-08-04	MT
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-03	CI
Newron Pharmaceuticals S.P.A. Announces Marco Caremi, Executive Vice President Business Development Will Leave the Company as Per End of June 2023	23-05-02	CI
Newron Pharmaceuticals Promotes Finance VP to CFO	23-05-02	MT
Newron Pharmaceuticals S.p.A. Presents Six-Month Interim Data from the First 100 Patients Randomized in Study 014/015 At the 31St European Congress of Psychiatry	23-03-28	CI
Newron Pharmaceuticals S.p.A. Reports Compelling Topline Results from All Patients in Study 014, its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Treatment-Resistant Schizophrenia	23-03-20	CI
Newron Pharmaceuticals' Schizophrenia Drug Shows Significant Improvement in Efficacy	23-03-20	MT
Transcript : Newron Pharmaceuticals S.p.A., 2022 Earnings Call, Mar 14, 2023	23-03-14

Chart Newron Pharmaceuticals S.p.A.

Duration

Period

More charts

Company Profile

Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinsonâs disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

Sector

Pharmaceuticals

Calendar

2024-05-12 - German Spring Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Newron Pharmaceuticals S.p.A.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.167 EUR

Average target price

13.28 EUR

Spread / Average Target

+85.31%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
NEWRON PHARMACEUTICALS S.P.A.	+37.98%	143M
CSL LIMITED	-2.86%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	40.86B
BIOGEN INC.	-21.94%	29.36B
UCB	+56.65%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-5.41%	17.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.23%	11.26B
INCYTE CORPORATION	-17.60%	11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.96%	11.31B
SWEDISH ORPHAN BIOVITRUM AB	+6.37%	8.31B

Biopharmaceuticals

Newron Pharmaceuticals S.p.A.

Equities

NWRN

IT0004147952

Pharmaceuticals

Newron Pharmaceuticals : launches a private placement of new shares.

Latest news about Newron Pharmaceuticals S.p.A.

Chart Newron Pharmaceuticals S.p.A.

Company Profile

Income Statement Evolution

Ratings for Newron Pharmaceuticals S.p.A.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals